Precisis GmbH

Precisis GmbH, based in Heidelberg, Germany, develops minimally invasive neurostimulation therapies for neurological disorders. Its flagship product, EASEE® (Epicranial Application of Stimulation Electrodes for Epilepsy), is a first-of-its-kind brain pacemaker for drug-resistant focal epilepsy. Implanted beneath the scalp without penetrating brain tissue, EASEE® reduces surgical risk, shortens recovery, and enhances patient comfort.

Clinical trials show 53% of patients saw reduced seizure frequency, with 17% becoming seizure-free. The CE-certified device is commercially available in parts of Europe, with U.S. regulatory efforts underway.

Led by CEO Karl Stoklosa, the company is focused on international growth, clinical validation, and expanding its adaptable technology platform to other conditions like depression, Parkinson’s, and chronic pain. In 2023, Precisis received the Innovation Award of Baden-Württemberg and maintains strong academic and clinical partnerships.

The company is seeking strategic partners to support growth through funding, mentoring, due diligence, financial guidance, and IP strategy—offering a strong opportunity to invest in a validated, high-impact MedTech solution.